A reminder that the OSD on Context of Use: Bridging Biomarker Strategy with Analytical Excellence will occur in just over a week. Looking forward to a robust discussion!
Disclaimer: Opinions expressed are solely my own and do not express the views or opinions of my employer.
Original Message:
Sent: 12-16-2024 09:47
From: Karen Quadrini
Subject: OSD on Wed. Jan 22, 2025 - Context of Use: Bridging Biomarker Strategy with Analytical Excellence (Part 2)
Hi Salvatore, I can send you a personal invite. You can also download a calendar invite with dial in from the Event tab located at the top of this community page. We started to post in the Event tab because of the download functionality. Reach out if you try this option and have any issues.
------------------------------
Karen Quadrini, PhD
Director, Clinical Biomarkers
Prothena Biosciences
Brisbane, CA
[email protected]
Disclaimer: Opinions expressed are solely my own and do not express the views or opinions of my employer.
Original Message:
Sent: 12-12-2024 10:36
From: Salvatore Iovino
Subject: OSD on Wed. Jan 22, 2025 - Context of Use: Bridging Biomarker Strategy with Analytical Excellence (Part 2)
Hi Karen, can you share an outlook meeting invite?
Thx
------------------------------
Salvatore Iovino
Sr. Director, DMPK and Bioanalytical Sciences
Editas Medicine
Newton MA
[email protected]
Disclaimer: Opinions expressed are solely my own and do not express the views or opinions of my employer.
Original Message:
Sent: 12-08-2024 20:46
From: Karen Quadrini
Subject: OSD on Wed. Jan 22, 2025 - Context of Use: Bridging Biomarker Strategy with Analytical Excellence (Part 2)
Please join for the second Open Scientific Discussion (OSD) in the Biomarker Strategy series hosted by the AAPS Biomarkers and Precision Medicine (BPM) and Gene and Cell Therapy Products (GCTP) Communities on January 22nd, 12 – 1 pm EST on the following topic:
Context of Use: Bridging Biomarker Strategy with Analytical Excellence (Part 2)
- What transforms a good biomarker strategy into a great one?
- How good does an assay need to be (where do we set the bar)?
- How does one select the appropriate analytical platform for biomarker assessments?
- Case studies of different context of use scenarios will be presented
Discussion Leaders:
- Yan Ni (Passage Bio)
- Karen Quadrini (Prothena Biosciences)
- Joel Mathews (Ionis Pharmaceuticals)
Organized by: Karen Quadrini (Prothena Biosciences), Carmen Fernández-Metzler (PharmaCadence), Ayuko Ota-Setlik (Regeneron)
We start at 12:00 EST sharp. To avoid interruptions, please dial in before noon and mute yourself until Q&A starts.
(Please remain on mute unless asking questions)
When: Wednesday, Jan 22, 2025 12pm – 1pm EST
Where: Please join from your computer, tablet or smartphone.
https://global.gotomeeting.com/join/305789893
You can also dial in using your phone.
United States: +1 (872) 240-3412
Access Code: 305-789-893
Join from a video-conferencing room or system.
Dial in or type: 67.217.95.2 or inroomlink.goto.com
Meeting ID: 305 789 893
Or dial directly: [email protected] or 67.217.95.2##305789893
New to GoToMeeting? Get the app now and be ready when your first meeting starts:
https://global.gotomeeting.com/install/305789893
Please feel free to share with colleagues who may be interested in this topic.
Thanks,
On Behalf of The Leadership Teams of the AAPS BPM and GCTP Communities
#biomarker #OSD #Contextofuse #OpenScientificDiscussions #Bioanalytical
------------------------------
Karen Quadrini, PhD
Director, Clinical Biomarkers
Prothena Biosciences
Brisbane, CA
[email protected]
Disclaimer: Opinions expressed are solely my own and do not express the views or opinions of my employer.
------------------------------